The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease: Effects of an Early Invasive or Noninvasive Strategy
Abstract
CONTEXT: Inflammatory activity is associated with high rates of long-term mortality in unstable coronary artery disease (CAD). Interleukin 6 (IL-6) induces C-reactive protein and fibrinogen, systemic markers of inflammation. OBJECTIVES: To determine whether plasma levels of IL-6 are predictive of mortality and to evaluate the interaction of IL-6 levels with the effects of invasive vs noninvasive treatment strategies in unstable CAD patients. DESIGN, SETTING, AND PATIENTS: The prospective, randomized Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease II trial, conducted among 3489 patients, 3269 of whom had plasma samples analyzed for IL-6 levels, with diagnosed unstable CAD (67% male; median age, 67 years) at 58 Scandinavian hospitals between June 1996 and August 1998. INTERVENTIONS: Patients were randomly assigned to receive either an early invasive (n = 1222) or a noninvasive treatment strategy (n = 1235). The latter group, as well as 666 patients with contraindications to invasive therapy, were further randomized to 90-day treatment with low-molecular-weight heparin (dalteparin, 5000-7500 IU twice per day; n = 1140) or placebo (n = 1127). MAIN OUTCOME MEASURE: Mortality at 6 and 12 months in the medically and interventionally randomized cohorts, respectively, in relation to IL-6 levels, measured at randomization. RESULTS: Plasma levels of IL-6 that were at least 5 ng/L compared with levels lower than 5 ng/L were associated with greatly increased mortality in the noninvasive group (7.9% vs 2.3%; relative risk [RR], 3.47; 95% confidence interval [CI], 1.94-6.21) and in the placebo-treated group (7.9% vs 2.5%; RR, 3.19; 95% CI, 1.77-5.74). The association remained significant after adjustment for most established risk indicators. An early invasive treatment strategy strongly reduced 12-month mortality among those with elevated IL-6 levels (5.1% absolute reduction; P =.004) whereas mortality was not reduced among patients without elevated IL-6 concentrations. Those taking dalteparin with elevated IL-6 levels experienced lower 6-month mortality than those who did not take dalteparin (3.5% absolute reduction; P =.08). CONCLUSIONS: Circulating IL-6 is a strong independent marker of increased mortality in unstable CAD and identifies patients who benefit most from a strategy of early invasive management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Ridker, P. M., Rifai, N., Stampfer, M. J., & Hennekens, C. H. (2000) · Circulation · doi:10.1161/01.cir.101.15.1767 · Cited by 2,429 · cited 5×
“Downloaded From: https://jama.jamanetwork.com/ by a Non-Human Traffic (NHT) User on 06/02/2019 tive of randomized strategy, for all patients with incapacitating symptoms, recurrence of instability, or MI. Aspirin was given to all patients on admission (initial dose, 300-600 mg; maintenance dose, 75-320 mg once daily),…”
BackgroundInfluentialKoenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,964
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488
Lindahl, B., Toss, H., Siegbahn, A., Venge, P., & Wallentin, L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431602 · Cited by 1,224
Self-citationTorre-Amione, G., Kapadia, S., Benedict, C., Oral, H., Young, J. B., & Mann, D. L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00589-7 · Cited by 1,211
Elevated Levels of Interleukin-6 in Unstable Angina
Biasucci, L. M., Vitelli, A., Liuzzo, G., Altamura, S., Caligiuri, G., Monaco, C., Rebuzzi, A. G., Ciliberto, G., & Maseri, A. (1996) · Circulation · doi:10.1161/01.cir.94.5.874 · Cited by 738
Wallentin, L., Lagerqvist, B., Husted, S., Kontny, F., Ståhle, E., & Swahn, E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02427-2 · Cited by 675
Self-citationSchieffer, B., Schieffer, E., Hilfiker-Kleiner, D., Hilfiker, A., Kovanen, P. T., Kaartinen, M., Nussberger, J., Harringer, W., & Drexler, H. (2000) · Circulation · doi:10.1161/01.cir.101.12.1372 · Cited by 654
Elevation of C-reactive protein in “active” coronary artery disease
Berk, B. C., Weintraub, W. S., & Alexander, R. W. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90079-g · Cited by 588
Toss, H., Lindahl, B., Siegbahn, A., Wallentin, L., & Group, F. T. F. S. (1997) · Circulation · doi:10.1161/01.cir.96.12.4204 · Cited by 520
Self-citationBiasucci, L. M., Liuzzo, G., Fantuzzi, G., Caligiuri, G., Rebuzzi, A. G., Ginnetti, F., Dinarello, C. A., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.16.2079 · Cited by 485
Mendall, M. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1982 · Cited by 357
Prabhu, S. D., Chandrasekar, B., Murray, D. R., & Freeman, G. L. (2000) · Circulation · doi:10.1161/01.cir.101.17.2103 · Cited by 265
Inflammatory Markers of Coronary Risk
Rader, D. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431609 · Cited by 260
Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6
Woods, A. (2000) · European Heart Journal · doi:10.1053/euhj.1999.2207 · Cited by 238
The biological effects of interleukin 6
Barton, B. E. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199601)16:1<87::aid-med3>3.0.co;2-q · Cited by 141
Verheggen, P. W. H. M. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1312 · Cited by 88
Simon, A. D., Yazdani, S., Wang, W., Schwartz, A. J., & Rabbani, L. E. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1018758409934 · Cited by 53
Cited by
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Brook, R. D., Franklin, B., Cascio, W., Hong, Y., Howard, G., Lipsett, M., Luepker, R., Mittleman, M., Samet, J., Smith, S. C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000128587.30041.c8 · Cited by 2,380
Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events
Granger, C. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2345 · Cited by 2,356
Gan, W. Q. (2004) · Thorax · doi:10.1136/thx.2003.019588 · Cited by 1,838
Metadata
- Authors
- Lindmark, E., Diderholm, E., Wallentin, L., & Siegbahn, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-11-07
- Volume
- 286
- Issue
- 17
- Pages
- 2107
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2165951067
- Cited by
- 556
- References
- 24
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.